Ν **Proportion** 95%-CI Effect size 2010-2012 26 11.4 (7.8; 16.4)2013-2015



(9.0; 17.9)

(10.0; 13.5)

Patients that discontinued due to adverse events by year category for phase 1 trials



11.6

121

2016-2019

2019-2021

Prediction interval

Overall

- (3.2:34.6)40 Effect size (95%-CI)

Test for subgroup differences: p = 0.333